Oral Nutritional Supplement with β-hydroxy-β-methylbutyrate (HMB) Improves Nutrition, Physical Performance and Ameliorates Intramuscular Adiposity in Pre-Frail Older Adults: A Randomized Controlled Trial.

Plain-language guide to PMID 34179932 (2021): open-label randomized controlled trial of Copper (Supplement).

Key Facts

PMID: 34179932
Journal: The journal of nutrition, health & aging
Year: 2021
Study type: Randomized Controlled Trial
Authors: Peng LN et al. (6 authors)
DOI: 10.1007/s12603-021-1621-7

What This Study Did, in Plain Language

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

This 12-week randomized controlled trial evaluated the changes of muscle mass, muscle strength, physical performance and intramuscular adiposity among community-dwelling pre-frail older persons.

Intramuscular adipose tissue (IMAT) and the mid-thigh cross-sectional area (CSA) of muscle were obtained by MRI, and the IMAT-to-CSA ratio was calculated to evaluate intramuscular adiposity.

Who Took Part

By PubMed's age tags, the people studied were older adults, both men and women.

This was an open-label, parallel group, randomized controlled trail that enrolled 70 community-dwelling pre-frail older persons without active or uncontrolled conditions, disability or dementia.

All participants received functional assessments, laboratory tests and magnetic resonance imaging (MRI) of the dominant leg before and after study.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Being open-label, the Copper (Supplement) study did not mask who received what.

The Copper (Supplement) group and the comparison group ran side by side rather than switching.

What Was Measured

The subject headings attached to it are Adiposity, Frail Elderly, Nutritional Status, Physical Functional Performance and Valerates.

Author keywords: Frailty, oral nutritional supplementation, sarcopenia, skeletal muscle and β-hydroxy-β-methylbutyrate.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Copper (Supplement).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (The journal of nutrition, health & aging), a journal based in France.

More context: the Copper (Supplement) compound page, all human trials.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Copper (Supplement) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.